All News

Results from a retrospective exploratory study of patients with urge incontinence and detrusor overactivity suggest that leakage and the pressure at which it occurs have potential predictive and therapeutic value.

The synergy between two large NIDDK-sponsored studies and pharmaceutical research will soon bring new treatments and etiologic insight to interstitial cystitis/bladder pain syndrome.

Web-based communication has become increasingly important for creating a more effective patient experience.

Cutting-edge research in andrology is changing the way urologists who specialize in male infertility ply their craft.

Urologists attending localized prostate cancer sessions at the upcoming AUA annual meeting in Washington will hear more about the ongoing debate on open versus minimally invasive radical prostatectomy, the use of 5-alpha-reductase inhibitors (5-ARIs) in men on active surveillance, and updates on treatment approaches such as high-intensity focused ultrasound.

Continuing progress in the area of tissue engineering holds the greatest potential impact, not just in pediatric urology or even the entire specialty, but for medicine and society as a whole.

Results from analyses of urodynamics data collected in the Trial of Mid-urethral Slings show some parameters change significantly after surgery.

Advancing technology is pushing clinicians and patients into making ever more nuanced decisions between the costs of a procedure and its value.

In the area of urologic infections and inflammation, research to be presented at this year's AUA annual meeting in Washington will highlight an ongoing trend toward understanding and attempting to modify the human microbiologic environment for patients' benefit.

Of the many questions raised by the advent of robot-assisted surgery, two are germane to robotic sacrocolpopexy: Does the technology increase the risk of stress urinary incontinence in women undergoing the robotic procedure, and if it does, should an anti-incontinence procedure accompany the primary procedure as prophylaxis against incontinence?

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes U.S. phase I and II localized prostate cancer trials that are currently recruiting participants as well as phase IV U.S. incontinence/overactive bladder trials. This list is current as of April 22, 2011. more information, view the complete database at http://ClinicalTrials.gov.

Research investigating the ability to detect low levels of circulating tumor cells and to correlate their quantity with clinicopathologic parameters in men with advanced prostate cancer who have undergone surgery or radiotherapy is still at an early stage, but the initial results suggest this method has promising prognostic value.

A number of the leading studies that focus on the epidemiology, etiology, and treatment of BPH and lower urinary tract symptoms being presented at the upcoming AUA annual meeting seem to be characterized more by the questions they raise than by those they answer.

The newest urology products and services from IPC Medical Corp., Mission Pharmacal, Microline Surgical, Inc., the American Medical Group Association, Uramix, Inc., WellComm, and Graceway Pharmaceuticals, Inc.

Urology drugs and devices that are in the pipeline from immatics biotechnologies GmbH, Neotract Inc., Abbott Laboratories, and Beech Tree Labs, Inc.

A retropubic mid-urethral sling showed a success rate of 81% and a satisfaction rate of 78% at an average follow-up of 68 months (range, 60-88 months) in a recent study.

Research suggests that urologists should be more candid with patients about the potential aftereffects of radical prostatectomy and other prostate interventions.

Edwin Posadas, MD, has joined Cedars-Sinai Medical Center, Los Angeles, as the clinical director of the genitourinary medical oncology program in the Samuel Oschin Comprehensive Cancer Institute.

Rare atypical fractures of the femur appear to be a class effect of bisphosphonates, according to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

A pelvic magnetic resonance imaging scan with intravenous contrast and rectal balloon is highly effective in identifying local recurrence even at low PSA values in prostate cancer patients with a rising or persistently elevated PSA after prostatectomy, according to research presented at the American Society for Radiation Oncology's Cancer Imaging and Radiation Therapy Symposium in Atlanta.

The FDA has announced steps to help reduce the risk of exposure to improperly reprocessed medical devices, including endoscopes, that can lead to the transmission of disease.

Acupuncture appears to provide long-lasting relief to hot flashes, heart palpitations, and anxiety due to side effects of hormone treatment for prostate cancer, according to a recent study.

Providers who indicated they received on call compensation, including urologists, were more likely to be compensated daily or annually in 2010 compared with previous years, recent survey results indicate.

In patients with low-grade prostate cancer, forgoing immediate radiation or radical prostatectomy poses no added risk of death, say researchers from Johns Hopkins University, Baltimore.

The 5-alpha-reductase inhibitor dutasteride (Avodart), when added to an active surveillance strategy, slows progression of prostate cancer in men with localized disease and decreases patient anxiety.

The survival benefits of abiraterone acetate remained consistent across a wide range of subgroups of men with castration-resistant prostate cancer that had progressed on docetaxel (Taxotere).